443

Sakakibara R.¹, Uchiyama T.¹, Yoshiyama M.¹, Hattori T.¹, Yamanishi T.² 1. Neurology Department Chiba University, 2. Urology Department Dokkyo Medical College

SYMPATHOMIMETIC DRUG AMELIORATES POSTURAL HYPOTENSION BUT MAY INCREASE THE RISK OF URINARY RETENTION

Aims of Study

Drugs act on vasoconstriction are one of the main streams of treating postural hypotension in patients with multiple system atrophy (MSA), i.e., Shy-Drager syndrome, that include midodrine, DOPS and amezinium. The lower urinary tract dysfunction is another autonomic feature in these patients, and both urinary urgency / frequency and voiding difficulty are common. We recently found that amezinium treatment may increase post-micturition residuals in MSA patents.

<u>Methods</u>

Five patients with MSA included 4 men and one woman, mean age 58 years, mean duration of disease 4.6 years. Cardiovascular and urinary function tests were made in all patients, who showed central and peripheral types of the dysfunctions. In particular, four of the patients had high urethral closure pressure and 2 had detrusor-sphincter dyssynergia. Post-micturition residual volumes and clinical symptoms were re-evaluated after 6 months' treatment with 15 mg/day of amezinium metilsulfate.

Results

After treatment, the mean systolic pressure fall in head-up tilting was decreased as compared to that before treatment (47 mmHg versus 51 mmHg for a change of 8%). The mean volume of post-micturition residuals was increased as compared to that before treatment (178 ml versus 113 ml for a change of 37%, p <0.05). A lessening in orthostatic dizziness was noted in three of five patients. None of the patients had change of their urinary filling symptoms. Voiding difficulty changed in none of four patients, but it appeared in one patient who had no voiding difficulty before the treatment. The increase in the volume of post-micturition residuals was related to none of the urodynamic parameters including detrusor-sphincter dyssynergia.

Conclusions

Our findings suggest that sympathomimetic agents may increase the risk of urinary retention in patients with MSA, most probably by stimulating both 1B-receptors in the vascular walls and 1A/D-receptors in the proximal urethra.

References

Bannister R, Mathias CJ. Management of postural hypotension. In: *Autonomic failure; a textbook of clinical disorders of the autonomic nervous system. Fourth edition.* Edited by Mathias CJ, Bannister R, Oxford University Press, Oxford, 1999: 342-356.

Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy; clinical features and treatment in 62 cases. *J Urol* 1994; 151: 1336-41.

Kita K, Hirayama K. Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug. Neurology 1988; 38: 1095-1099.

Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, Egoshi K, Sekita N. Are alphablockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. *J Auton Nerv Syst* 2000; 79: 191-195.



Figure 1 Systolic pressure fall on head-up tilting and postmicturition residuals before and after amezinium treatemnt. bar: mean volume of residual urine